EUCTR2007-001955-20-DE进行中（未招募）不适用
A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND ANTIRETROVIRAL ACTIVITY OF DERMAVIR (LC002) PATCH IN TREATMENT-NAÏVE HIV-1-INFECTED PATIENTS
Genetic Immunity Kft.0 个研究点开始时间: 2007年8月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •10.1.1 Age: =18 and =50 years.
- •10.1.2 Chronic HIV infection, for the purpose of the study defined as:
- •confirmed time point of seroconversion for HIV antibodies at least 6
- •months before study entry and no signs of symptomatic acute HIV
- •infection in the 12 months before study entry.
- •10.1.3 Plasma HIV RNA value =5,000 copies/mL and = 150,000 c/mL.
- •10.1.4 Patients must be antiretroviral therapy naïve
- •10.1.5 Documented CD4+ T-cell count at screening =400 cells/mm3.
- •10.1.6 Female study volunteers who are participating in sexual activity that could lead to pregnancy must agree to use two reliable methods of contraception, one of which must be a barrier method. A barrier method of contraception (condoms or cervical cap) together with another reliable form of contraception (condoms, with a spermicidal agent; a diaphragm or cervical cap with spermicide; an IUD; or hormonal-based contraception) must be used while receiving vaccine and for 6 weeks after stopping the vaccine. Condoms are recommended because their appropriate use is the only contraception method effective for preventing HIV-1 transmission. Sexually active female study volunteers without reproductive potential are eligible without requiring the use of contraception. Written documentation of missing reproductive potential needs to be confirmed by study investigator before vaccination.
- •10.1.7 Male patients participating in the study must agree to not attempt to impregnate a female, or participate in sperm donation programs. Males engaging in sexual activity that could lead to pregnancy must use a condom from the date of receipt of the first study vaccine until six weeks after receipt of the last study vaccine. This needs to be documented in written form by study investigator and patient before vaccination.
- •10.1.8 Patient must be able and willing to provide signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •10.2.1 Clinically relevant skin disease as determined by the investigator, such as:
- •Active atopic dermatitis
- •Active or history of psoriasis
- •Active urticaria
- •Known hypersensitivity to adhesive tape or Tegaderm®
- •History of keloid
- •Active or history of vitiligo
- •Melasma (acquired hyperpigmentation disorder)
- •Acute or chronic skin infections or history of recurrent skin infections
- •10.2.2 Patients with tattoos, or changes in pigmentation at the selected skin immunization sites, will be excluded, if the study investigator decides this would have an impact on the study.
- •10.2.3 Active acute or chronic illness (e.g Hepatitis C) that is in the opinion of the investigator clinically relevant and a contra-indication for enrollment in the study including active severe clinical HIV disease complications (all CDC clinical Category C complications, see Appendix III).
- •10.2.4 Diagnosis of any chronic autoimmune diseases (e.g. Grave’s) or bleeding disorder that is in the opinion of the investigator clinically relevant and a contra-indication for enrollment in the study or insulin dependent diabetes mellitus.
- •10.2.5 Greater than or equal to Grade 2 values for any of the following laboratory tests at screening, will be excluded [standard international units in italics].
- •Hemoglobin (Hgb) [less than or equal to 8.4 g/dL (less than or equal to 5.2 mmol/dl)]
- •Absolute neutrophil count (ANC) [less than or equal to 999/mm3, =0.999 x 109/L]
- •Platelets, decreased [less than or equal to 99,999/mm3, =99.999 x 109/L]
- •Liver Function Tests (LFTs) ALT (SGPT)/AST (SGOT) [greater than or equal to 2.5 times the upper limit of normal (ULN)]
- •Creatinine [greater than or equal to 1.5 x ULN]-use age and sex appropriate values (per DAIDS Table)
- •Total bilirubin [greater than or equal to 2.0 x ULN]
- •Any other clinical and laboratory toxicity (=Grade 2) that is in the opinion of the investigator clinically relevant and a contra-indication for enrollment in the study.
- •10.2.6 Prior treatment with any HIV vaccine.
- •10.2.7 Treatment with any immune modulating agents (e.g. IL-2, IFN-?, GM-CSF) or chemotherapy for malignancy within 12 months prior to screening.
- •10.2.8 Receipt of any immunizations or vaccinations within 28 days of entry into this study.
- •10.2.9 Systemic steroid therapy within the past 28 days.
- •10.2.10 Breast-feeding.
- •10.2.11 Pregnancy.
- •10.2.12 Excessive exposure to the sun (sunbathing, tanning beds) or laser hair removal/tattoo removal etc. at or near the vaccine site within 2 weeks prior to study entry.
- •10.2.13 Participation in any clinical trial of an experimental drug or device in the previous 30 days
- •10.2.14 Patients with malignancy within 12 month prior to screening.
研究者
相似试验
进行中（未招募）
1 期
EFFICACY AND SAFETY STUDY OF GED-0507-34-LEVO (GED0507) FOR TREATMENT OF PATIENTS WITH ACTIVE ULCERATIVE COLITISlcerative ColitisMedDRA version: 20.0Level: LLTClassification code 10021184Term: IBDSystem Organ Class: 100000016704MedDRA version: 20.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000016670MedDRA version: 20.0Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000016670MedDRA version: 20.0Level: SOCClassification code 10017947Term: Gastrointestinal disordersSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-001684-36-BGPPM SERVICES SA207
进行中（未招募）
1 期
Clinical trial that will compare the efficacy and safety of apremilast versus placebo, in patients with active ulcerative colitis, a chronic inflammatory of the colon of unknown origiEUCTR2014-002981-64-NLCelgene Corporation165
进行中（未招募）
1 期
EFFICACY AND SAFETY STUDY OF GED-0507-34-LEVO (GED0507) FOR TREATMENT OF PATIENTS WITH ACTIVE ULCERATIVE COLITISEUCTR2016-001684-36-HUPPM SERVICES SA207
进行中（未招募）
1 期
Clinical trial that will compare the efficacy and safety of apremilast versus placebo, in patients with active ulcerative colitis, a chronic inflammatory of the colon of unknown origiSubjects with active ulcerative colitisMedDRA version: 20.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2014-002981-64-DECelgene Corporation165
已完成
2 期
A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY<br>TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004)<br>FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITISChronic colon inflammation10017969Ulcerative colitisNL-OMON45076Celgene Corporation9